enGene Holdings Inc. (NASDAQ:ENGNW – Get Free Report)’s stock price traded down 15.9% during mid-day trading on Wednesday . The company traded as low as $0.81 and last traded at $0.95. 8,493 shares traded hands during mid-day trading, an increase of 82% from the average session volume of 4,656 shares. The stock had previously closed at $1.13.
enGene Price Performance
The stock has a fifty day moving average price of $1.19 and a 200-day moving average price of $1.33.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Further Reading
- Five stocks we like better than enGene
- Stock Market Sectors: What Are They and How Many Are There?
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- 3 Tickers Leading a Meme Stock Revival
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- What is the S&P/TSX Index?
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
